nat-bendamustine powder for solution
natco pharma (canada) inc - bendamustine hydrochloride - powder for solution - 25mg - bendamustine hydrochloride 25mg - antineoplastic agents
nat-bendamustine powder for solution
natco pharma (canada) inc - bendamustine hydrochloride - powder for solution - 100mg - bendamustine hydrochloride 100mg - antineoplastic agents
bendamustine hydrochloride 2.5mg/ml powder for concentrate for solution for infusion (25mg vial)
fresenius kabi italia s.r.l via camagre 41, 37063 isola della scala (vr) , italy - powder for concentrate for solution for infusion - bendamustine hydrochloride 2.5 mg/ml - antineoplastic agents
bendamustine hydrochloride 2.5mg/ml powder for concentrate for solution for infusion(100mg vial)
fresenius kabi italia s.r.l via camagre 41, 37063 isola della scala (vr) , italy - powder for concentrate for solution for infusion - bendamustine hydrochloride 2.5 mg/ml - antineoplastic agents
ribomustin 100 mg
astellas pharma international b.v., israel - bendamustine hydrochloride - powder for concentrate for solution for infusion - bendamustine hydrochloride 100 mg - bendamustine - first-line of chronic lymphocytic leukaemia (binet stage b or c) in patients for whom fludarabine combination chemotheraphy is not appropiate. indolent non-hodgkin’s lymphomas as monotheraphy in patients, who have progressed during or within 6 months following treatment with rituximab or a rituximab containing regimen. follicular non-hodgkin’s lymphoma as first line treatment in combination with rituximab.
ribomustin 25 mg
astellas pharma international b.v., israel - bendamustine hydrochloride - powder for concentrate for solution for infusion - bendamustine hydrochloride 25 mg - bendamustine - first-line of chronic lymphocytic leukaemia (binet stage b or c) in patients for whom fludarabine combination chemotheraphy is not appropiate. indolent non-hodgkin’s lymphomas as monotheraphy in patients, who have progressed during or within 6 months following treatment with rituximab or a rituximab containing regimen. follicular non-hodgkin’s lymphoma as first line treatment in combination with rituximab.
ribomustin 100 mg
dor pharmaceutical services ltd., israel - bendamustine hydrochloride - powder for concentrate for solution for infusion - bendamustine hydrochloride 100 mg/vial - bendamustine - first-line of chronic lymphocytic leukaemia (binet stage b or c) in patients for whom fludarabine combination chemotheraphy is not appropiate. indolent non-hodgkin’s lymphomas as monotheraphy in patients, who have progressed during or within 6 months following treatment with rituximab or a rituximab containing regimen.follicular non-hodgkin’s lymphoma as first line treatment in combination with rituximab.
ribomustin 25 mg
dor pharmaceutical services ltd., israel - bendamustine hydrochloride - powder for concentrate for solution for infusion - bendamustine hydrochloride 25 mg/vial - bendamustine - first-line of chronic lymphocytic leukaemia (binet stage b or c) in patients for whom fludarabine combination chemotheraphy is not appropiate. indolent non-hodgkin’s lymphomas as monotheraphy in patients, who have progressed during or within 6 months following treatment with rituximab or a rituximab containing regimen. follicular non-hodgkin’s lymphoma as first line treatment in combination with rituximab.
bendamustine 100mg powder for concentrate for solution for infusion vials
accord-uk ltd - bendamustine hydrochloride - powder for solution for infusion - 100mg
bendamustine 25mg powder for concentrate for solution for infusion vials
medac uk - bendamustine hydrochloride - powder for solution for infusion - 25mg